Choreo LLC Boosts Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Choreo LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 98.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,015 shares of the medical equipment provider’s stock after purchasing an additional 998 shares during the quarter. Choreo LLC’s holdings in Intuitive Surgical were worth $680,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Portside Wealth Group LLC increased its position in Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the period. Kades & Cheifetz LLC purchased a new stake in Intuitive Surgical in the 4th quarter valued at about $230,000. Blair William & Co. IL grew its holdings in Intuitive Surgical by 3.1% in the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after buying an additional 11,400 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after buying an additional 129,194 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $371.70 on Thursday. The stock’s 50 day moving average price is $385.79 and its 200 day moving average price is $348.35. The firm has a market capitalization of $131.85 billion, a PE ratio of 67.09, a price-to-earnings-growth ratio of 4.79 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.00 EPS. On average, analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ISRG. Truist Financial lifted their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Barclays lifted their price target on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. BTIG Research lifted their price target on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a report on Friday, April 19th. StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Finally, Royal Bank of Canada boosted their target price on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Myriam Curet sold 481 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $386.09, for a total value of $185,709.29. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $115,054.82. The disclosure for this sale can be found here. Insiders have sold a total of 226,928 shares of company stock valued at $87,833,828 in the last three months. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.